Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).”
From Hypoglycemia (2018) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Research works printed but not linked: 1
- Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press
Cited by
Items 601–700 of 879
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9351-6 · Cited by 5
Chiquete, E., & Lavalle-Gonzalez, F. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s107437 · Cited by 5
McCreedy, E. M., Kane, R. L., Gollust, S. E., Shippee, N. D., & Clark, K. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.02.170141 · Cited by 7
Comprehensive Review on Diabetes Associated Cardiovascular Complications - The Vitamin D Perspective
Durgarao, Y., Manjrekar, P., Adhikari, P., Mahabala, C., & Rukmini, M. S. (2019) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x19666190114155302 · Cited by 5
Accelerated atherosclerotic cardiovascular risk in type 1 diabetes mellitus: Time for a new idea?
Rao, A. D., Vaz, C. L., & Williams, K. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.04.207 · Cited by 6
Cardiac Autonomic Neuropathy in Diabetes Mellitus Patients – Are We Aware of the Consequences?
Moțățăianu, A., Bărcuţean, L., Maier, S., Bălașa, A. F., & Stoian, A. (2020) · Acta Marisiensis. Seria Medica · doi:10.2478/amma-2020-0003 · Cited by 5
Zhu, J., Li, W., Chen, F., Xie, Z., Zhuo, K., & Huang, R. (2023) · Insights into Imaging · doi:10.1186/s13244-022-01357-7 · Cited by 5
Coombes, J. S., Dias, K. A., Lal, R., Fassett, R. G., Wallen, M. P., Ramos, J. S., Russell, S., Vear, N. K., Gajanand, T., Bailey, T. G., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110701 · Cited by 7
Baltzis, D., Grammatikopoulou, M. G., Παπάνας, Ν., Trakatelli, C., Kintiraki, E., Hassapidou, M. N., & Manes, C. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0300-2 · Cited by 5
Success of a sports-club led-community X-PERT Diabetes Education Programme
Morgan, A., Drew, D., Clifford, A., & Hull, K. (2016) · Sport in Society · doi:10.1080/17430437.2016.1173923 · Cited by 5
Glycemic Key Metrics and the Risk of Diabetes-Associated Complications
Kohnert, K., Heinke, P., Zander, E., Vogt, L., & Salzsieder, E. (2016) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2016-0047 · Cited by 5
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00562-5 · Cited by 6
Self-citationManagement of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Glycemic Control in Older Adults: Applying Recent Evidence to Clinical Practice
Sood, A. K., & Aron, D. C. (2009) · Cited by 7
Daramola, O. F. (2012) · SUNScholar (Stellenbosch University) · Cited by 5
Physical activity in diabetes: Is any better than none?
Carson, A. P., Williams, L. B., & Hill, A. N. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.10.012 · Cited by 5
Li, Y., Liu, Y., Li, J., Zhou, H., & Ma, H. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00886-5 · Cited by 4
AlBurno, H., Schneider, F., de Vries, H., Mohannadi, D. A., & Mercken, L. A. G. (2022) · F1000Research · doi:10.12688/f1000research.123468.1 · Cited by 8
Management of Type 2 Diabetes Mellitus
Marks, J. B. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_8 · Cited by 5
Wang, H., Tang, Z., Xu, L. L., Hu, B., & Feng, B. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12188 · Cited by 4
Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., & Giugliano, D. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0134 · Cited by 4
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia
Mintz, M. L., & Minervini, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.880674 · Cited by 6
Ming-ming, C. A. O., & Tong, N. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00133.x · Cited by 4
Initiating a glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes mellitus.
Gavin, J. R. (2012) · PubMed · Cited by 4
Update on Diabetes Medical Management: Epidemiology and Treatment
Chertman, L. S., Neuman, D., & Vendrame, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-33286-0_18 · Cited by 4
Lipid and glucose metabolism in centenarians: risk factors of cardiovascular diseases and frailty
Eruslanova, K. A., Matchekhina, L. V., Dudinskaya, Е. N., Kotovskaya, Y. V., Андреевич, Г. Д., Govorun, V. M., & Ткачева, О. Н. (2021) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2020-294-304 · Cited by 4
Younas, A., Riaz, J., Chughtai, T., Maqsood, H., Younus, S., Qasim, M. I., Saim, M., Qazi, S., Khaliq, M., & Fatima, M. (2021) · Cureus · doi:10.7759/cureus.13045 · Cited by 5
Opportunities for diabetes research using the Norwegian Cardiovascular Disease Registry
Egeland, G. M., Sundvor, V., Igland, J., Seliussen, I. H., Klakegg, Y., Vollset, S. E., Akerkar, R. R., Tell, G. S., & Ebbing, M. (2013) · Norsk Epidemiologi · doi:10.5324/nje.v23i1.1608 · Cited by 4
The Role of Diet in the Prevention and Treatment of Diabetes
Wylie‐Rosett, J., & Delahanty, L. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00031-x · Cited by 11
Epidemiologic Characterization of Risk for Cardiovascular Diseases
Maki, K. C., Dicklin, M. R., & Nieman, K. M. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_1 · Cited by 5
Alijanvand, M. H., Aminorroaya, A., Kazemi, I., Yamini, S. A., Janghorbani, M., Amini, M., & Mansourian, M. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s189726 · Cited by 5
Prediabetes. A new paradigm for early prevention of cardiovascular disease
Demidova, T. Y., & Plakhotnyaya, V. M. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-14-124-132 · Cited by 4
Ahmad, J., Zubair, M., Malik, N., Doddigarla, Z., & Raghav, A. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.10.010 · Cited by 4
Risk of Diabetes and Cardiovascular Disease: Best to Return Back to the Basics
DEEDWANIA, P. C. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.333 · Cited by 4
Self-citationPharmacological Management of Type 2 Diabetes in Newly Diagnosed Older Adults
Spain, M. P., & Edlund, B. J. (2009) · Journal of Gerontological Nursing · doi:10.3928/00989134-20090527-03 · Cited by 5
After Cardiac Surgery, How Does Nutrition Fit in With Risk Factors?
KONES, R. J. (2009) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607109343111 · Cited by 4
Continuing Improvement in Type 2 Diabetes Care Through Performance-Based Evaluations
Baum, H. B. A., Cagliero, E., Berry, C. A., Mencia, W. A., Stowell, S. A., & Miller, S. C. (2014) · Journal of Primary Care & Community Health · doi:10.1177/2150131913518438 · Cited by 5
Weir, M. R. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12929 · Cited by 4
Glycemia and cardiovascular diseases in type 2 diabetes
Skyler, J. S. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02276.x · Cited by 4
Self-citationKnowledge of and Adherence to health advice among adults with diabetes in Libya
Elkharam, W. M. (2016) · Liverpool John Moores University · doi:10.24377/ljmu.t.00004467 · Cited by 4
Intensive Glucose Lowering in Cardiovascular Risk Management: Unsolved Questions
Shimabukuro, M., Masuzaki, H., & Sata, M. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0062 · Cited by 3
Аржиматова, Г. Ш., Hejlo, T. S., Novova, N. L., & Suchkova, O. V. (2019) · Russian Annals of Ophthalmology · doi:10.17116/oftalma201913502155 · Cited by 5
Expert Opinion Statement on Continuous Glucose Monitoring in Type 2 Diabetes in the Arab Gulf Region
Alshaikh, A., BAKHSH, A. M. K., Alsagheir, A., El-Laboudi, A. H., Al-Mohanadi, D. H., Alawadi, F., Elbadawi, H., Alzubaidi, L. M. Y., Al‐Sofiani, M. E., Farooqi, M. H., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251393740 · Cited by 4
Tactics in counselling patients to start insulin
Lee, Y. K., Lee, P. Y., & Ng, C. J. (2012) · Diabetic Medicine · doi:10.1111/dme.12050 · Cited by 3
Rapid-acting insulin glulisine: an update on clinical experience
DAILEY, G. E. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.40 · Cited by 4
Beale, E., Wa, L., & Chan, L. (2010) · Practical Diabetes · doi:10.1002/pdi.1506 · Cited by 3
Addressing barriers to effective basal insulin therapy.
Mohan, V., John, M., Baruah, M. P., & Bhansali, A. (2014) · PubMed · Cited by 5
Goyat, R., Rai, P., Chang, J., Ponte, C. D., & Tan, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0639-z · Cited by 3
Kumar, S., Talwalkar, P., Das, S., & Goswami, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_161_17 · Cited by 3
Mohammad, I., George, J., Zimmerman, J., & Elteriefi, R. (2022) · INNOVATIONS in pharmacy · doi:10.24926/iip.v13i2.4815 · Cited by 5
Gonzalvo, J. D., Meredith, A. H., Pastakia, S. D., Peters, M., Eberle, M., Schmelz, A. N., Pence, L. M., Triboletti, J. S., & Walroth, T. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282940 · Cited by 4
Uchida, T., Kawai, J., Fujitani, Y., Kawamori, R., Watada, H., & Hirose, T. (2010) · Diabetology International · doi:10.1007/s13340-010-0002-y · Cited by 4
Evidence-based prescribing of diabetes medications: are we getting closer?
Bellary, S., Tahrani, A. A., & Barnett, A. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30020-6 · Cited by 3
Letunica, N., Cai, T., Cameron, F. J., Monagle, P., Ignjatović, V., & Attard, C. (2021) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202000060 · Cited by 3
Stroke risk factors: impact and management
Pedelty, L., & Gorelick, P. B. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139344296.022 · Cited by 5
Das, U. N. (2010) · World Journal of Diabetes · doi:10.4239/wjd.v1.i4.101 · Cited by 3
Orozco‐Beltrán, D., Fernández, C. D. L. S., Gil-Guillén, V. F., Carratalá‐Munuera, C., & Pérez, J. N. (2010) · Atención Primaria · doi:10.1016/s0212-6567(10)70004-4 · Cited by 6
How to Obtain Appropriate Type 2 Diabetes Control in the First 180 Days of Treatment Initiation
Kuritzky, L., Epstein, B. J., & Lavernia, F. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2140 · Cited by 3
Botts, A., & Munshi, M. N. (2008) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-008-0068-2 · Cited by 3
Norgaard, M. L., Andersson, C., Hansen, P. R., Andersen, S. S., Vaag, A. A., Schramm, T. K., Folke, F., Køber, L., Torp-Pedersen, C. T., & Gislason, G. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-5 · Cited by 3
Implications of New Diabetes Treatment Trials: Should Current Clinical Practice be Altered?
Kravetz, J. D., & Federman, D. G. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2004 · Cited by 3
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2012) · Cited by 3
Self-citationThe evolving frontier of diabetes therapy: The renaissance of glycemology
Ceriello, A., Genovese, S., & Bosi, E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.036 · Cited by 3
Attitude and Compliance with the Onset of Insulin Therapy in Patients with Type 2 Diabetes
Davoudi, Z., Chouhdari, A., Mir, M., & Akbarian, F. (2020) · Shiraz E-Medical Journal · doi:10.5812/semj.95408 · Cited by 6
Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
Goldberg, R. B. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.582826 · Cited by 3
Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., & Creager, M. A. (2014) · Cited by 2
Self-citationCoronary Artery Bypass Grafting in Patients with Diabetes Mellitus: A Cardiologist’s View
Bezdenezhnykh, N. A., Nikolaevich, S. A., Викторович, Б. А., & Leonidovna, B. O. (2017) · InTech eBooks · doi:10.5772/intechopen.70416 · Cited by 2
Kondalkar, V. S., Polshettiwar, P. P., Choudhari, G. B., Pawar, A. T., & Choudhari, V. P. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100756 · Cited by 5
Arrieta, F., Piñera, M., Iglesias, P., Nogales, P., Salinero-Fort, M. Á., Abanades, J. C., Botella-Carretero, J. I., Calañas, A., Balsa, J. A., Zamarrón, I., et al. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.09.002 · Cited by 2
Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung
Wehling, M., Burkhardt, H., Schwarz, S. T., Frölich, L., & Wedding, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-48126-4_2 · Cited by 2
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_70 · Cited by 2
Kockaya, G., & Wertheimer, A. I. (2011) · INNOVATIONS in pharmacy · doi:10.24926/iip.v2i2.228 · Cited by 2
Palumbo, P. J., & Wert, J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8564 · Cited by 2
Mata‐Cases, M. (2012) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(12)70010-7 · Cited by 2
Aspectos prácticos en la insulinización del paciente anciano con diabetes
Díaz, M. S. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65004-1 · Cited by 3
Ismail‐Beigi, F., Lombardero, M. S., Escobedo, J., GENUTH, S. M., Green, J., Massaro, E. M., Mooradian, A. D., Ovalle, F., Whitehouse, F. W., & Zonszein, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.01.006 · Cited by 2
Coronary Artery Calcium: A Clue to the Enigma of Tight Glycemic Control and Cardiovascular Disease?
Bertoni, A. G., & Kitzman, D. W. (2009) · Diabetes · doi:10.2337/db09-1097 · Cited by 3
Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk
Reboldi, G., Gentile, G., Angeli, F., Mazzotta, G., Martire, P., Garofoli, M., & Verdecchia, P. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0077-9 · Cited by 2
Shiga, T., Yokokawa, H., Taneda, Y., Sugihara, E., Meijyo, M., Mitsuhashi, K., Hisaoka, T., & Isonuma, H. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0049-4 · Cited by 2
AGEs as a Preventable Cause of Diabetes and its Complications
Vlassara, H. (2011) · Cited by 2
Hypoglycemic Morbidity and Mortality in Diabetes
Son, J. W. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.1.17 · Cited by 2
Hudson, M., & Palermo, N. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-20317-1_14-1 · Cited by 2
Diabetes and Cardiovascular Disease
Coutiño-Castelán, D., Abundes-Velasco, A., Santos, F. D. D. L., Arias, E., González, C. M., Ortíz, A. M., Morales, J. L., Cruz, J. L. B. D. L., Fonseca, C. E. H., & Custodio-Sánchez, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_46 · Cited by 2
(SFD), U. P. D. P. P. P. L. S. F. D. D. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70660-0 · Cited by 2
Management of Type 2 Diabetes Mellitus
Dungan, K. M., & Buse, J. B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00048-4 · Cited by 3
Self-citationFeng, D., Huang, S., Lang, X., Liu, Y., & Zhang, K. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2310337 · Cited by 2
Diabetes in an Undergraduate Class
Watve, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4409-1_3 · Cited by 2
Shi, L., Ye, X., Lü, M., Wu, E. Q., Sharma, H., Thomason, D., Zhang, M., Wang, Y., & Fonseca, V. A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0122-2 · Cited by 2
The importance of combined glycemic control in patients with type 2 diabetes mellitus
Кононенко, И. В., & Smirnova, O. M. (2010) · Problems of Endocrinology · doi:10.14341/probl201056543-51 · Cited by 2
Pathophysiology and Management of Type 1 Diabetes
Georga, E. I., Fotiadis, D. I., & Tigas, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804831-3.00002-9 · Cited by 4
Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice
Abdelfattah, O., Hassanein, M., Saad, A. M., Abela, G. S., & Aldasouqi, S. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200107103829 · Cited by 2
Antoniou, S., Naka, K. Κ., Bechlioulis, A., Papadakis, M., Tsatsoulis, A. A., Michalis, L. K., & Tigas, S. K. (2021) · HORMONES · doi:10.1007/s42000-021-00318-x · Cited by 5
Initial Diagnosis and Management of Type 2 Diabetes Mellitus
Suda, N., & Lee, H. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-84367-0_39 · Cited by 2
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Nouveaux traitements du diabète de type 2: quelles stratégies thérapeutiques pour demain?
Halimi, S., Debaty, I., & Guedel, D. (2009) · Sang thrombose vaisseaux · doi:10.1684/stv.2009.0418 · Cited by 3
Translating Sweetness: Type 2 Diabetes, Race, Research, and Outreach
Battle, J. (2012) · eScholarship (California Digital Library) · Cited by 3
Carlos Zavala, U., & U., F. F. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.04.006 · Cited by 6
Metabolic and Endocrine Diseases
Studnička, J., Karhanová, M., Gabalec, F., Stěpanov, A., Blaha, V., Lášticová, M., Kalitová, J., & Schovánek, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-58592-0_5 · Cited by 1
Evans, M., Lewis, E. D., Joseph, A., Crowley, D., & Guthrie, N. (2025) · Journal of Food Science and Technology · doi:10.1007/s13197-025-06414-9 · Cited by 1
Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice
Mohan, V., Makkar, B. M., Saboo, B., Jagadisha, A., Chawla, M. S., Deshpande, N., Goyal, V. K., & Kapoor, R. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_50_25 · Cited by 3
Metadata
- Authors
- Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
- Affiliations
- University of Miami (US)
- Park Nicollet Clinic (US)
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of California, San Francisco (US)
- University of Bristol (GB)
- American Diabetes Association (US)
- Saint Luke's Hospital (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-01-01
- Volume
- 32
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2606812
- OpenAlex
- W2181092548
- Cited by
- 881
- References
- 22
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- Sanofi
- Edwards Lifesciences
- Osiris Therapeutics
- Insulet Corporation
- MannKind Corporation
- Halozyme
- Dexcom
- Tandem Diabetes Care
- Daiichi-Sankyo
- Novo Nordisk
- Pfizer Pharmaceuticals
- Daiichi Sankyo Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.